Overview

Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The aim of the trail is investigate the effect of liraglutide 1.8mg as add-on to insulin for 6 months on carotid intima media thickness and cardiovascular risk factors in subjects with type 1 diabetes mellitus.
Phase:
Phase 3
Details
Lead Sponsor:
David Sanchez Garcia
Collaborator:
Instituto Mexicano del Seguro Social
Treatments:
Liraglutide